Clinical Trials · NCT02787447
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- First People's Hospital of Hangzhou
- Enrollment
- 46
- Start date
- May 2016
- Locations
- 1 site, China
- Primary endpoint
- The proportion of patients with an abscopal response assessed at 1-6 months after the radiation therapy